‘FOCUSING ON TECH FOR NUCLEIC ACID MEDICINE’

“The speed of product development has been proven to be the most dominant factor during this pandemic. A 4-year project starting in 2022 has been awarded for DCB to further design novel technologies & platforms for nucleic acid medicine. The ‘drug targeting and delivery’ & complex medicine will be of our particular interest to develop in 2022. Further advanced gene-editing technologies could also be applied for the “off-the-shelf” cell therapy potentially using iPS cells. Aiming to take on challenge & preparation for the next pandemic & with the anticipated 2-year maturation of DCB-developed technologies for the short- & long-chain nucleic acid drugs, the factory of contract development & manufacturing organisation (CDMO) services for nucleic acid drugs & smart medicine shall also be established. Moreover, we would also take advantage of Taiwan’s ICT industries & govt policies in promoting the biomedical industry to not only assist in drug development but also to provide informatics solutions to precision health. In the aspect of business prospective, DCB will focus on the potential therapeutic on tumor microenvironment, especially anti-CD73 antibodies, & CHO-C high-yield cell line system for developing recombinant proteins with clinical usages.”

- DR TSAI-KUN LI, Vice President, Development Center for Biotechnology (DCB), Taiwan